HC Wainwright Issues Positive Estimate for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a note issued to investors on Thursday, July 30th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings per share of ($1.27) for the quarter, up from their prior estimate of ($1.55). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.12) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.32) EPS, FY2026 earnings at ($5.96) EPS, FY2027 earnings at ($4.78) EPS, FY2028 earnings at ($3.53) EPS and FY2029 earnings at ($1.82) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%.The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million.

Several other research firms have also weighed in on AGIO. Citigroup lifted their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday. Royal Bank Of Canada raised their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Bank of America lifted their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $40.88.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $30.54 on Monday. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -4.36 and a beta of 0.58. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00. The stock’s 50 day moving average price is $34.53 and its two-hundred day moving average price is $30.92.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AGIO. T. Rowe Price Investment Management Inc. bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth about $25,000. Assetmark Inc. boosted its stake in Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 362 shares during the last quarter. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals during the 1st quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd bought a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $49,000. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $72,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.